JP2020508042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508042A5 JP2020508042A5 JP2019544016A JP2019544016A JP2020508042A5 JP 2020508042 A5 JP2020508042 A5 JP 2020508042A5 JP 2019544016 A JP2019544016 A JP 2019544016A JP 2019544016 A JP2019544016 A JP 2019544016A JP 2020508042 A5 JP2020508042 A5 JP 2020508042A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- composition according
- component
- inhibitor
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023047827A JP2023082054A (ja) | 2017-02-17 | 2023-03-24 | 細胞医療用の標的リガンド－ペイロードによる薬剤デリバリー |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762460118P | 2017-02-17 | 2017-02-17 | |
| US62/460,118 | 2017-02-17 | ||
| PCT/US2018/018557 WO2018152451A1 (en) | 2017-02-17 | 2018-02-17 | Targeted ligand-payload based drug delivery for cell therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023047827A Division JP2023082054A (ja) | 2017-02-17 | 2023-03-24 | 細胞医療用の標的リガンド－ペイロードによる薬剤デリバリー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508042A JP2020508042A (ja) | 2020-03-19 |
| JP2020508042A5 true JP2020508042A5 (https=) | 2021-04-01 |
| JP7288402B2 JP7288402B2 (ja) | 2023-06-07 |
Family
ID=63170493
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019544016A Active JP7288402B2 (ja) | 2017-02-17 | 2018-02-17 | 細胞医療用の標的リガンド－ペイロードによる薬剤デリバリー |
| JP2023047827A Pending JP2023082054A (ja) | 2017-02-17 | 2023-03-24 | 細胞医療用の標的リガンド－ペイロードによる薬剤デリバリー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023047827A Pending JP2023082054A (ja) | 2017-02-17 | 2023-03-24 | 細胞医療用の標的リガンド－ペイロードによる薬剤デリバリー |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12343403B2 (https=) |
| EP (2) | EP3583218B1 (https=) |
| JP (2) | JP7288402B2 (https=) |
| KR (1) | KR102595249B1 (https=) |
| CN (2) | CN118634339B (https=) |
| AU (1) | AU2018221171B2 (https=) |
| CA (1) | CA3053534A1 (https=) |
| ES (1) | ES3024357T3 (https=) |
| WO (1) | WO2018152451A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| JP2019508036A (ja) | 2016-02-16 | 2019-03-28 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 免疫療法組成物及び方法 |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| CA3053534A1 (en) * | 2017-02-17 | 2018-08-23 | Purdue Research Foundation | Targeted ligand-payload based drug delivery for cell therapy |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| US12312416B2 (en) | 2018-02-06 | 2025-05-27 | Seattle Children's Hospital | Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors |
| AU2019225174B2 (en) | 2018-02-23 | 2025-11-20 | Endocyte, Inc. | Sequencing method for CAR T cell therapy |
| CA3096458A1 (en) | 2018-04-12 | 2019-10-17 | Umoja Biopharma, Inc. | Viral vectors and packaging cell lines |
| JP2021530444A (ja) | 2018-06-28 | 2021-11-11 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 |
| CN112543651B (zh) * | 2018-08-07 | 2023-06-02 | 普渡研究基金会 | 使car t细胞恢复活力 |
| MX2021008824A (es) * | 2019-01-23 | 2021-10-13 | Univ Johns Hopkins | Análogos no inmunosupresores de tacrolimus (fk506) y uso de los mismos. |
| CN114207135A (zh) | 2019-06-11 | 2022-03-18 | 夏尔人类遗传性治疗公司 | 用于治疗由失调的血浆激肽释放酶介导的疾病的抗体的腺相关病毒载体递送 |
| WO2021044373A2 (en) * | 2019-09-06 | 2021-03-11 | Avectas Limited | Engineering of immune cells for ex vivo cell therapy applications |
| WO2021081280A1 (en) | 2019-10-23 | 2021-04-29 | Shire Human Genetic Therapies, Inc. | Adeno-associated virus vectors based gene therapy for hereditary angioedema |
| CN115210252A (zh) | 2020-02-04 | 2022-10-18 | 西雅图儿童医院（Dba西雅图儿童研究所） | 抗二硝基苯酚的嵌合抗原受体 |
| WO2022044024A1 (en) * | 2020-08-31 | 2022-03-03 | Ramot At Tel-Aviv University Ltd. | Small molecule modulators of gsk-3 activity |
| WO2022130014A1 (en) | 2020-12-16 | 2022-06-23 | Takeda Pharmaceutical Company Limited | Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein |
| WO2022140556A1 (en) * | 2020-12-22 | 2022-06-30 | Eutropics Pharmaceuticals, Inc. | Methods and compositions related to bcl2 and bim heterodimer antibodies |
| CN113462649B (zh) * | 2021-05-27 | 2022-08-23 | 浙江大学 | Mek抑制剂在减少car-t细胞耗竭和终末分化中的应用 |
| IL310057A (en) * | 2021-07-21 | 2024-03-01 | Immunitybio Inc | Generation of chimeric antigen receptor mRNA molecules for expression in primary NK cells |
| CN116041545A (zh) * | 2022-12-12 | 2023-05-02 | 南方医科大学 | 一种靶向荧光素或生物素的通用型car及其应用 |
| WO2024206913A2 (en) * | 2023-03-31 | 2024-10-03 | Northwestern University | Compositions for antigen-specific immune cell activation |
| WO2026012294A1 (zh) * | 2024-07-09 | 2026-01-15 | 深圳虹信生物科技有限公司 | 一种治疗b细胞过度增殖产生自身抗体所引起的疾病的药物、方法与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9523469D0 (en) * | 1995-11-16 | 1996-01-17 | Sandoz Ltd | Organic compounds |
| US6093382A (en) | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
| ES2502366T3 (es) * | 2001-03-09 | 2014-10-03 | Board Of Regents, The University Of Texas System | Inducción de inmunidad tumoral por variantes de proteína de unión a folato |
| US20080260812A1 (en) * | 2004-04-26 | 2008-10-23 | Takami Matsuyama C/O Kagoshima University | Therapeutic Medicine Containing Monoclonal Antibody Against Folate Receptor Beta (Fr-Beta) |
| EP2419120A4 (en) * | 2009-04-08 | 2016-01-06 | Univ California | HUMAN PROTEIN CONCERNS WITH CONTROLLED SERUM PHARMACOKINETICS |
| CA2785373A1 (en) * | 2009-12-23 | 2011-06-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| WO2016098078A2 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Dimerization switches and uses thereof |
| WO2016164745A1 (en) * | 2015-04-10 | 2016-10-13 | The Methodist Hospital System | Cd117 ligand-drug conjugates for targeted cancer therapy |
| WO2017027843A1 (en) * | 2015-08-12 | 2017-02-16 | Massachusetts Institute Of Technology | Cell surface coupling of nanoparticles |
| EP3402495A4 (en) * | 2016-01-15 | 2019-06-19 | Etubics Corporation | METHOD AND COMPOSITIONS FOR T-CELL IMMUNOTHERAPY |
| EP3529268B1 (en) * | 2016-10-19 | 2025-02-26 | The Scripps Research Institute | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
| LT3535392T (lt) * | 2016-11-02 | 2024-04-25 | Universität Basel | Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje |
| CA3053534A1 (en) | 2017-02-17 | 2018-08-23 | Purdue Research Foundation | Targeted ligand-payload based drug delivery for cell therapy |
-
2018
- 2018-02-17 CA CA3053534A patent/CA3053534A1/en active Pending
- 2018-02-17 EP EP18754879.7A patent/EP3583218B1/en active Active
- 2018-02-17 WO PCT/US2018/018557 patent/WO2018152451A1/en not_active Ceased
- 2018-02-17 CN CN202410423409.8A patent/CN118634339B/zh active Active
- 2018-02-17 JP JP2019544016A patent/JP7288402B2/ja active Active
- 2018-02-17 KR KR1020197026818A patent/KR102595249B1/ko active Active
- 2018-02-17 AU AU2018221171A patent/AU2018221171B2/en active Active
- 2018-02-17 CN CN201880024308.6A patent/CN110662839A/zh active Pending
- 2018-02-17 US US16/486,632 patent/US12343403B2/en active Active
- 2018-02-17 ES ES18754879T patent/ES3024357T3/es active Active
- 2018-02-17 EP EP25163099.2A patent/EP4600267A3/en active Pending
-
2023
- 2023-03-24 JP JP2023047827A patent/JP2023082054A/ja active Pending
-
2025
- 2025-04-30 US US19/194,112 patent/US20250262313A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508042A5 (https=) | ||
| Goldstein et al. | Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging | |
| Luo et al. | Cholangiocyte endothelin 1 and transforming growth factor β1 production in rat experimental hepatopulmonary syndrome | |
| JP2022051847A (ja) | 悪性脳腫瘍における標的化粒子の浸透、分布および応答のための組成物及び方法 | |
| Guenter et al. | Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment | |
| Miao et al. | Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein | |
| Eigl et al. | A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195 | |
| MA43090A1 (fr) | Peptides, combinaisons de peptides et médicaments basés sur les cellules pour l'immunothérapie contre le cancer de la vessie urinaire et d'autres cancers | |
| AU2018250336A1 (en) | Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods | |
| Beer et al. | Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes | |
| Ren et al. | PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a 177Lu-labeled αPD-L1 antibody | |
| MA42381B1 (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers | |
| Kwon et al. | 64Cu-labeled trastuzumab fab-PEG24-EGF radioimmunoconjugates bispecific for HER2 and EGFR: pharmacokinetics, biodistribution, and tumor imaging by PET in comparison to monospecific agents | |
| Rafei-Shamsabadi et al. | Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone | |
| CN115103633B (zh) | 使用多种成像剂的成像方法 | |
| BRPI0511126A (pt) | métodos de tratamento utilizando proteìnas de ligação de albumina como alvos | |
| Miller et al. | ENaC γ-expressing astrocytes in the circumventricular organs, white matter, and ventral medullary surface: sites for Na+ regulation by glial cells | |
| Roof et al. | Immunotherapy in HPV-related oropharyngeal cancers | |
| Tolmachev et al. | Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels | |
| Osborne et al. | Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment | |
| Ku et al. | MicroSPECT/CT imaging of cell-line and patient-derived EGFR-positive tumor xenografts in mice with panitumumab Fab modified with hexahistidine peptides to enable labeling with 99mTc (I) tricarbonyl complex | |
| TW201604281A (zh) | 用以標的黑色素瘤相關抗原a3胜肽之寡核苷酸適體及其用途 | |
| Fazekas et al. | Why man's best friend, the dog, could also benefit from an anti-HER-2 vaccine | |
| Altai et al. | Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine | |
| Ferris et al. | Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma |